BCRX.US BioCryst Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
7.61 USD
Close of Nov 14, 2026
6.23 11.22
Market cap
USD 1.96B
P/E
-
P/B
56.59x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BCRX.US undervalued?

Graham number

The Graham number of BioCryst Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioCryst Pharmaceuticals Inc fundamental analysis

No fundamental analysis for BioCryst Pharmaceuticals Inc yet.

BioCryst Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton …

Full company profile